Annexon Files Q1 2025 10-Q, Details Financials

Ticker: ANNX · Form: 10-Q · Filed: May 12, 2025 · CIK: 1528115

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals, capital-raise

TL;DR

Annexon's Q1 2025 10-Q is in. Cash and investments detailed, ATM program active.

AI Summary

Annexon, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including cash and cash equivalents and short-term investments. Key events mentioned include the "TwoZeroTwoFourAtTheMarketProgram" and the "SalesAgreementWithCowenAndCompanyLLC".

Why It Matters

This filing provides investors with an update on Annexon's financial health and ongoing capital-raising activities as of the first quarter of 2025.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Annexon faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What was the total cash and cash equivalents as of March 31, 2025?

The filing indicates 'us-gaap:CashAndCashEquivalentsMember' for the period ending March 31, 2025, but the specific dollar amount is not provided in this excerpt.

What is the purpose of the 'TwoZeroTwoFourAtTheMarketProgram'?

The filing mentions the 'TwoZeroTwoFourAtTheMarketProgram' in relation to the sales agreement with Cowen and Company, LLC, suggesting it's a program for selling stock.

What is Annexon's Standard Industrial Classification?

Annexon, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.

When was the 'SalesAgreementWithCowenAndCompanyLLCMember' established or relevant?

The sales agreement is mentioned in relation to the periods ending March 31, 2025, and March 31, 2024, indicating its ongoing relevance.

Are there any specific accounting standards updates mentioned for this period?

Yes, the filing references 'us-gaap:AccountingStandardsUpdate202307Member' for the period ending March 31, 2025.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 by William H. Carson regarding Annexon, Inc. (ANNX).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing